BioStock: Cereno's CEO – "very excited for topline readout!"

Cereno Scientific has released its Q2 report for 2024, highlighting the company's advancements in developing cardiovascular disease treatments. CEO Sten R Sörensen came by the BioStock Studio to discuss the main takeaways from the period and take a sneak peak into what's to come for the company during Q3.

Watch the interview at biostock.se:

Cereno's CEO: "very excited for topline readout!" - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/